Chest wall pain after single-fraction thoracic stereotactic ablative Radiotherapy: Dosimetric analysis from the iSABR trial

Single-fraction stereotactic ablative radiotherapy (SABR) is a safe and effective therapy for non-central lung tumors [1 –3]. Three randomized trials have found similar local control and toxicity rates when comparing single versus multi-fraction SABR [1–3]. Compared to fractionated regimens, single-fraction SABR is more cost-effective with less time burden for patients [4,5]. Chest wall toxicity is less well studi ed for single-fraction SABR, however, and there is debate as to whether proximity to the chest wall is a relative contraindication for single-fraction treatment [6].

Source: Radiotherapy and Oncology - April 26, 2024 Category: Radiology Authors: Brianna Lau, Yufan F. Wu, Sunan Cui, Jie Fu, Scott Jackson, Daniel Pham, Piotr Dubrowski, Shaila Eswarappa, Lawrie Skinner, Hiroki Shirato, Hiroshi Taguchi, Michael F. Gensheimer, Harriet Gee, Alexander L. Chin, Maximilian Diehn, Billy W. Loo, Vitali Mois Source Type: research